Research Papers

This database includes peer-reviewed publications authored by TB Alliance staff. Use the tags on the left to filter by subject, or search for a particular author or term using the search bar.

Tag: Editorials

Displaying 50 papers

Grand Convergence: Aligning Technologies & Realities in Global Health

Publication: Yamey G, Morel C. Investing in Health Innovation: A Cornerstone to Achieving Global Health Convergence. PLOS Biology. 2016 Mar 1;14(3). doi: 10.1371/journal.pbio.1002389.

3/2016

Tags: Advocacy, Editorials, Policy, TB Burden

Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults

Publication: Furin J., Alirol E, Allen E, et. al. Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults. Int J Tuberc Lung Dis. 20161 Mar; 20(3): 290-294.

3/2016

Tags: Clinical Development, Editorials, MDR-TB, Trial Design, XDR-TB

Investing in Health Innovation: A Cornerstone to Achieving Global Health Convergence

Publication: Yamey G, Morel C. Investing in Health Innovation: A Cornerstone to Achieving Global Health Convergence. PLOS Biology. 2016 Mar 1;14(3). doi: 10.1371/journal.pbio.1002389.

3/2016

Tags: Advocacy, Editorials, Policy, TB Burden

Understanding and addressing the tuberculosis case detection gap national inventory studies to improve estimates of incidence and strengthen surveillance

Publication: Sismanidis C, Glaziou P, Bloss E, et. al. Understanding and addressing the tuberculosis case detection gap national inventory studies to improve estimates of incidence and strengthen surveillance. 2016 Mar.

3/2016

Tags: Advocacy, Editorials, MDR-TB, Policy, TB Burden, TB Drug Market, TB Market

"Understanding and addressing the tuberculosis case detection gap national inventory studies to improve estimates of incidence and strengthen surveillance" with comments

Publication: Sismanidis C, Glaziou P, Bloss E, et. al. "Understanding and addressing the tuberculosis case detection gap national inventory studies to improve estimates of incidence and strengthen surveillance" with comments. 2016 Mar

3/2016

Tags: Advocacy, Editorials, MDR-TB, Policy, TB Burden, TB Drug Market, TB Market

The Zika Loopholes: The FDA has a smart-sounding program to drive research for neglected diseases—with two big flaws

Publication: Brock WR, Cohen R, Cone J, McKenna L. The Zika Loopholes: The FDA.... March 25, 2016. http://www.politico.com/agenda/story/2016/03/the-right-way-to-encourage-companies-to-develop-a-treatment-for-zika-000079. Accessed March 25, 2016.

3/2016

Tags: Editorials

Paediatric formulations of second-line anti-tuberculosis medications: challenges and considerations

Publication: Taneja R, Garcia-Prats AJ, Furin J, Maheshwari HK. Paediatric formulations of second-line anti-tuberculosis medications: challenges and considerations. Int J Tuberc Lung Dis. 2015 Dec;19 Suppl 1:61-8. doi: 10.5588/ijtld.15.0435.

12/2015

Tags: Advocacy, Childhood TB, Editorials, MDR-TB, Regimen Change

Towards early inclusion of children in tuberculosis drugs trials: a consensus statement

Publication: Nachman S, Ahmed A, Amanullah, et. al. Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. Lancet Infect Dis. 2015 Jun;15(6):711-20. doi: 10.1016/S1473-3099(15)00007-9.

5/2015

Tags: Advocacy, Childhood TB, Clinical Development, Editorials, Policy, Trial Design

The Tuberculosis Drug Discovery and Development Pipeline and Emerging Drug Targets

Publication: Mdluli K, Kaneko T, Upton A. The tuberculosis drug discovery and development pipeline and emerging drug targets.Cold Spring Harb Perspect Med. 2015 Jan 29;5(6). pii: a021154. doi: 10.1101/cshperspect.a021154.

1/2015

Tags: Advocacy, Clinical Development, Drug Discovery, Editorials, Global Pipeline, MDR-TB

Strengthening neglected tropical disease research through enhancing research-site capacity: an evaluation of a novel web application to facilitate research collaborations

Publication: Furtado T, Franzen S, van Loggerenberg F, et. al. Strengthening neglected tropical disease research through enhancing research-site capacity: an evaluation of a novel web application to facilitate research collaborations. PLoS Negl Trop Dis. 2014 Nov 13;8

11/2014

Tags: Advocacy, Clinical Development, Editorials, Policy

Tuberculosis drug discovery and emerging targets

Publication: Mdluli K, Kaneko T, Upton A. Tuberculosis drug discovery and emerging targets. Ann N Y Acad Sci. 2014 Sep;1323:56-75. doi: 10.1111/nyas.12459.

6/2014

Tags: Advocacy, Drug Discovery, Drug Targets, Editorials, Preclinical Models

Requirements for the clinical evaluation of new anti-tuberculosis agents in children

Publication: Donald PR, Ahmed A, Burman WJ, et. al. Requirements for the clinical evaluation of new anti-tuberculosis agents in children. Int J Tuberc Lung Dis. 2013 Jun;17(6):794-9. doi: 10.5588/ijtld.12.0567.

6/2013

Tags: Advocacy, Childhood TB, Clinical Development, Editorials, Trial Design

The role of product development partnerships in advancing the development of drugs for unmet needs

Publication: Breitstein J, Spigelman M. The role of product development partnerships in advancing the development of drugs for unmet needs. Clin Pharmacol Ther. 2013 Jun;93(6):468-70. doi: 10.1038/clpt.2013.53.

6/2013

Tags: Advocacy, Editorials, Global Pipeline

Engaging communities in tuberculosis research

Publication: Boulanger RF, Seidel S, Lessem E, et. al. Engaging communities in tuberculosis research. Lancet Infect Dis. 2013 Jun;13(6):540-5. doi: 10.1016/S1473-3099(13)70042-2.

6/2013

Tags: Advocacy, Community Engagement, Editorials

Aligning New Tuberculosis Drug Regimens and Drug Susceptibility Testing- A Needs Assessment and Roadmap for Action

Publication: Wells WA, Boehme CC, Cobelens FGJ, et. al. Aligning New Tuberculosis Drug Regimens and Drug Susceptibility Testing: A Needs Assessment and Roadmap for Action. Lancet Infect Dis. 2013;13(5):449-458. doi:10.1016/S1473-3099(13)70025-2.

3/2013

Tags: Advocacy, Drug-Sensitivity Testing, Editorials, TB Market

Reply to "Contradictory results with high-dosage rifamycin in mice and humans"

Publication: Nuermberger EL, Rosenthal IM, Tasneen R, et. al. Reply to "Contradictory results with high-dosage rifamycin in mice and humans". Antimicrob Agents Chemother. 2013 Feb;57(2):1104-5. doi: 10.1128/AAC.02216-12

2/2013

Tags: Drug Discovery, Editorials, Pharmacodynamics, Preclinical Models, Rifapentine

Early bactericidal activity of new drug regimens for tuberculosis - Authors' reply

Publication: Diacon AH, Donald PR, Mendel CM. Early bactericidal activity of new drug regimens for tuberculosis - Authors' reply. Lancet. 2013 Jan 12;381(9861):112-3. doi: 10.1016/S0140-6736(13)60042-2.

1/2013

Tags: Clinical Development, Editorials, Moxifloxacin, NC-001, PaMZ, Pretomanid/PA-824, Pyrazinamide, Trial Design

Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis

Publication: Franzblau SG, DeGroote MA, Cho SH, et. al. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb). 2012 Nov;92(6):453-88. doi: 10.1016/j.tube.2012.07.003.

11/2012

Tags: Advocacy, Drug Discovery, Editorials, Preclinical Models

Multidrug-resistant tuberculosis

Publication: D'Ambrosio L, Centis R, Migliori GB. Multidrug-resistant tuberculosis. N Engl J Med. 2012 Nov 29;367(22):2154; author reply 2155-6. doi: 10.1056/NEJMc1210001#SA1.

11/2012

Tags: Advocacy, Clinical Development, Editorials, Trial Design

The multi-step process of building TB/HIV collaboration in Cambodia

Publication: Eang MT, Vun MC, Eam KK, et. al. The multi-step process of building TB/HIV collaboration in Cambodia. Health Res Policy Syst. 2012 Oct 18;10:34. doi: 10.1186/1478-4505-10-34.

10/2012

Tags: Advocacy, Editorials, Policy, TB Market, TB-HIV

Pages